Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Pain Relief Satisfaction With New Educational Materials: Complete Statistical AnalysisIndependent statistical analysis of Pain Relief Satisfaction With New Educational Materials: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03698773).
- Pain Study of Rectus Muscle Closure at Cesarean Delivery: Complete Statistical AnalysisIndependent statistical analysis of Pain Study of Rectus Muscle Closure at Cesarean Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00505362).
- Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma: Complete Statistical AnalysisIndependent statistical analysis of Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening: Complete Statistical AnalysisIndependent statistical analysis of Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PAL-HFIndependent statistical analysis of Palliative Care in Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01589601).
- PALACEIndependent statistical analysis of Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: Complete Statistical AnalysisIndependent statistical analysis of Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PALLASIndependent statistical analysis of PALbociclib CoLlaborative Adjuvant Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513394).
- Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PALSIndependent statistical analysis of Physical Activity and Leisure-time Study (PALS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01342471).
- PAMMIndependent statistical analysis of Physiological Augmentation of Mindfulness Meditation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02754557).
- PANAMAIndependent statistical analysis of PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pancreas Resection With and Without Drains: Complete Statistical AnalysisIndependent statistical analysis of Pancreas Resection With and Without Drains: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01441492).
- Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02588339).
- Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01105312).
- Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…
- PANORAMA_3Independent statistical analysis of Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02654990).
- PANTHEONIndependent statistical analysis of A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size…
- PANTHERIndependent statistical analysis of Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD): primary endpoint results, effect estimate…
- PANTHERIndependent statistical analysis of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML): primary…
- Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions: Complete Statistical AnalysisIndependent statistical analysis of Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00835588).
- PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088413).
- Paracervical Block for Pain Associated With Laminaria Insertion: Complete Statistical AnalysisIndependent statistical analysis of Paracervical Block for Pain Associated With Laminaria Insertion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02454296).
- Paracetamol With Caffeine to Treat Episodic Tension Type Headache: Complete Statistical AnalysisIndependent statistical analysis of Paracetamol With Caffeine to Treat Episodic Tension Type Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01755702).
- paradigm™5Independent statistical analysis of Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- paradigm™6Independent statistical analysis of Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PARADYSEIndependent statistical analysis of A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT: Complete Statistical AnalysisIndependent statistical analysis of Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02575079).
- PARAGON-HFIndependent statistical analysis of Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction: primary endpoint results, effect estimate with confidence interval,…
- Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ParicalcitolIndependent statistical analysis of The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations: Complete Statistical AnalysisIndependent statistical analysis of PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris: Complete Statistical AnalysisIndependent statistical analysis of Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris: primary endpoint results, effect estimate with confidence interval,…
- PArTNERIndependent statistical analysis of PATient Navigator to rEduce Readmissions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02114515).
- PARTNER-MHIndependent statistical analysis of Improving Patient-Provider Communication to Reduce Mental Health Disparities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04515771).
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers: Complete Statistical AnalysisIndependent statistical analysis of Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PARTRIDGEIndependent statistical analysis of A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment: primary endpoint results, effect estimate with confidence interval,…
- PaSIndependent statistical analysis of Ready to Sail: Evaluating Sailing's Feasibility as Ergotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06397443).
- PAS2Independent statistical analysis of Bronchial Thermoplasty in Severe Persistent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01350336).
- PASCALRegistryIndependent statistical analysis of Edwards PASCAL Transcatheter Valve Repair System Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04443218).
- PASSIndependent statistical analysis of Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PASS DEGENIndependent statistical analysis of The Degen Study: Post-market Clinical Follow-up on the PASS LP, PASS Degen and PASS Tulip Systems (PASS DEGEN): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PassItOnIndependent statistical analysis of Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…